1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Veterinary Molecular Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Product Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product Type, 2017–2031
        6.3.1. Instruments & Software
        6.3.2. Kits & Reagents
        6.3.3. Services
    6.4. Market Attractiveness, by Product Type
7. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Technology
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Technology, 2017–2031
        7.3.1. Conventional PCR
        7.3.2. Singleplex PCR
        7.3.3. Multiplex PCR
        7.3.4. Real-time PCR
        7.3.5. Others
        7.3.6. 7.4 Market Attractiveness, by Technology
8. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, By Disease Type
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, By Disease Type, 2017–2031
        8.3.1. Vector-borne Diseases
        8.3.2. Respiratory Pathogens
        8.3.3. Diarrhea Pathogens
        8.3.4. Others
    8.4. Market Attractiveness, By Disease Type
9. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Animal Type
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Animal Type, 2017–2031
        9.3.1. Companion Animal
        9.3.2. Livestock Animal
    9.4. Market Attractiveness, by Animal Type
10. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by End-user
    10.1. Introduction and Definitions
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by End-user, 2017–2031
        10.3.1. Hospitals/Clinics
        10.3.2. Reference Laboratories
    10.4. Market Attractiveness, by End-user
11. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region, 2017–2031
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness, by Region
12. North America Veterinary Molecular Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product Type, 2017–2031
        12.2.1. Instruments & Software
        12.2.2. Kits & Reagents
        12.2.3. Services
    12.3. Market Attractiveness, by Product Type
    12.4. Market Value Forecast, by Technology, 2017–2031
        12.4.1. Conventional PCR
        12.4.2. Singleplex PCR
        12.4.3. Multiplex PCR
        12.4.4. Real-time PCR
        12.4.5. Others
    12.5. Market Attractiveness, by Technology
    12.6. Market Value Forecast, By Disease Type, 2017–2031
        12.6.1. Vector-borne Diseases
        12.6.2. Respiratory Pathogens
        12.6.3. Diarrhea Pathogens
        12.6.4. Others
    12.7. Market Attractiveness, By Disease Type
    12.8. Market Value Forecast, by Animal Type, 2017–2031
        12.8.1. Companion Animal
        12.8.2. Livestock Animal
    12.9. Market Attractiveness, by Animal Type
    12.10. Market Value Forecast, by User End-user, 2017–2031
        12.10.1. Hospitals/Clinics
        12.10.2. Reference Laboratories
    12.11. Market Attractiveness, by End-user
    12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.12.1. U.S.
        12.12.2. Canada
    12.13. Market Attractiveness Analysis
        12.13.1. By Product Type
        12.13.2. By Technology
        12.13.3. By Disease Type
        12.13.4. By Animal Type
        12.13.5. By End-user
        12.13.6. By Country
13. Europe Veterinary Molecular Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product Type, 2017–2031
        13.2.1. Instruments & Software
        13.2.2. Kits & Reagents
        13.2.3. Services
    13.3. Market Attractiveness, by Product Type
    13.4. Market Value Forecast, by Technology, 2017–2031
        13.4.1. Conventional PCR
        13.4.2. Singleplex PCR
        13.4.3. Multiplex PCR
        13.4.4. Real-time PCR
        13.4.5. Others
    13.5. Market Attractiveness, by Technology
    13.6. Market Value Forecast, By Disease Type, 2017–2031
        13.6.1. Vector-borne Diseases
        13.6.2. Respiratory Pathogens
        13.6.3. Diarrhea Pathogens
        13.6.4. Others
    13.7. Market Attractiveness, By Disease Type
    13.8. Market Value Forecast, by Animal Type, 2017–2031
        13.8.1. Companion Animal
        13.8.2. Livestock Animal
    13.9. Market Attractiveness, by Animal Type
    13.10. Market Value Forecast, by User End-user, 2017–2031
        13.10.1. Hospitals/Clinics
        13.10.2. Reference Laboratories
    13.11. Market Attractiveness, by End-user
    13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.12.1. Germany
        13.12.2. U.K.
        13.12.3. France
        13.12.4. Italy
        13.12.5. Spain
        13.12.6. Rest of Europe
    13.13. Market Attractiveness Analysis
        13.13.1. By Product Type
        13.13.2. By Technology
        13.13.3. By Disease Type
        13.13.4. By Animal Type
        13.13.5. By End-user
        13.13.6. By Country/Sub-region
14. Asia Pacific Veterinary Molecular Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product Type, 2017–2031
        14.2.1. Instruments & Software
        14.2.2. Kits & Reagents
        14.2.3. Services
    14.3. Market Attractiveness, by Product Type
    14.4. Market Value Forecast, by Technology, 2017–2031
        14.4.1. Conventional PCR
        14.4.2. Singleplex PCR
        14.4.3. Multiplex PCR
        14.4.4. Real-time PCR
        14.4.5. Others
    14.5. Market Attractiveness, by Technology
    14.6. Market Value Forecast, By Disease Type, 2017–2031
        14.6.1. Vector-borne Diseases
        14.6.2. Respiratory Pathogens
        14.6.3. Diarrhea Pathogens
        14.6.4. Others
    14.7. Market Attractiveness, By Disease Type
    14.8. Market Value Forecast, by Animal Type, 2017–2031
        14.8.1. Companion Animal
        14.8.2. Livestock Animal
    14.9. Market Attractiveness, by Animal Type
    14.10. Market Value Forecast, by User End-user, 2017–2031
        14.10.1. Hospitals/Clinics
        14.10.2. Reference Laboratories
    14.11. Market Attractiveness, by End-user
    14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.12.1. China
        14.12.2. Japan
        14.12.3. India
        14.12.4. Australia & New Zealand
        14.12.5. Rest of Asia Pacific
    14.13. Market Attractiveness Analysis
        14.13.1. By Product Type
        14.13.2. By Technology
        14.13.3. By Disease Type
        14.13.4. By Animal Type
        14.13.5. By End-user
        14.13.6. By Country/Sub-region
15. Latin America Veterinary Molecular Diagnostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Product Type, 2017–2031
        15.2.1. Instruments & Software
        15.2.2. Kits & Reagents
        15.2.3. Services
    15.3. Market Attractiveness, by Product Type
    15.4. Market Value Forecast, by Technology, 2017–2031
        15.4.1. Conventional PCR
        15.4.2. Singleplex PCR
        15.4.3. Multiplex PCR
        15.4.4. Real-time PCR
        15.4.5. Others
    15.5. Market Attractiveness, by Technology
    15.6. Market Value Forecast, By Disease Type, 2017–2031
        15.6.1. Vector-borne Diseases
        15.6.2. Respiratory Pathogens
        15.6.3. Diarrhea Pathogens
        15.6.4. Others
    15.7. Market Attractiveness, By Disease Type
    15.8. Market Value Forecast, by Animal Type, 2017–2031
        15.8.1. Companion Animal
        15.8.2. Livestock Animal
    15.9. Market Attractiveness, by Animal Type
    15.10. Market Value Forecast, by User End-user, 2017–2031
        15.10.1. Hospitals/Clinics
        15.10.2. Reference Laboratories
    15.11. Market Attractiveness, by End-user
    15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.12.1. Brazil
        15.12.2. Mexico
        15.12.3. Rest of Latin America
    15.13. Market Attractiveness Analysis
        15.13.1. By Product Type
        15.13.2. By Technology
        15.13.3. By Disease Type
        15.13.4. By Animal Type
        15.13.5. By End-user
        15.13.6. By Country/Sub-region
16. Middle East & Africa Veterinary Molecular Diagnostics Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Product Type, 2017–2031
        16.2.1. Instruments & Software
        16.2.2. Kits & Reagents
        16.2.3. Services
    16.3. Market Attractiveness, by Product Type
    16.4. Market Value Forecast, by Technology, 2017–2031
        16.4.1. Conventional PCR
        16.4.2. Singleplex PCR
        16.4.3. Multiplex PCR
        16.4.4. Real-time PCR
        16.4.5. Others
    16.5. Market Attractiveness, by Technology
    16.6. Market Value Forecast, By Disease Type, 2017–2031
        16.6.1. Vector-borne Diseases
        16.6.2. Respiratory Pathogens
        16.6.3. Diarrhea Pathogens
        16.6.4. Others
    16.7. Market Attractiveness, By Disease Type
    16.8. Market Value Forecast, by Animal Type, 2017–2031
        16.8.1. Companion Animal
        16.8.2. Livestock Animal
    16.9. Market Attractiveness, by Animal Type
    16.10. Market Value Forecast, by User End-user, 2017–2031
        16.10.1. Hospitals/Clinics
        16.10.2. Reference Laboratories
    16.11. Market Attractiveness, by End-user
    16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
        16.12.1. GCC Countries
        16.12.2. South Africa
        16.12.3. Rest of Middle East & Africa
    16.13. Market Attractiveness Analysis
        16.13.1. By Product Type
        16.13.2. By Technology
        16.13.3. By Disease Type
        16.13.4. By Animal Type
        16.13.5. By End-user
        16.13.6. By Country/Sub-region
17. Competition Landscape
    17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    17.2. Market Share Analysis, by Company (2022)
    17.3. Company Profiles
        17.3.1. IDEXX Laboratories, Inc.
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Product Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. Thermo Fisher Scientific, Inc.
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Product Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. Zoetis, Inc.
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Product Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. Neogen Corporation
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Product Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. bioMérieux SA
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Product Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. QIAGEN N.V.
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Product Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. Biomedica Medizinprodukte GmbH
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Product Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. Bioneer
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Product Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Mars, Incorporated
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Product Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview
        17.3.10. Innovative Diagnostics
            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.10.2. Product Portfolio
            17.3.10.3. Financial Overview
            17.3.10.4. SWOT Analysis
            17.3.10.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			